NCT06934382 - Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

May 30, 2029

Study Completion Date

May 30, 2031

Conditions

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL

Allogeneic anti-CD7 CAR-T cells (BEAM-201)

The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia